TW201336526A - 非水性液體組成物 - Google Patents

非水性液體組成物 Download PDF

Info

Publication number
TW201336526A
TW201336526A TW102103410A TW102103410A TW201336526A TW 201336526 A TW201336526 A TW 201336526A TW 102103410 A TW102103410 A TW 102103410A TW 102103410 A TW102103410 A TW 102103410A TW 201336526 A TW201336526 A TW 201336526A
Authority
TW
Taiwan
Prior art keywords
aqueous liquid
liquid composition
range
tocopherol
drug
Prior art date
Application number
TW102103410A
Other languages
English (en)
Chinese (zh)
Inventor
山田和人
愛路德 烏魯茲
麥可基路德 樸魯麥斯達
Original Assignee
參天製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 參天製藥股份有限公司 filed Critical 參天製藥股份有限公司
Publication of TW201336526A publication Critical patent/TW201336526A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW102103410A 2012-01-31 2013-01-30 非水性液體組成物 TW201336526A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012018062 2012-01-31

Publications (1)

Publication Number Publication Date
TW201336526A true TW201336526A (zh) 2013-09-16

Family

ID=48905235

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102103410A TW201336526A (zh) 2012-01-31 2013-01-30 非水性液體組成物

Country Status (12)

Country Link
US (1) US20150011518A1 (cg-RX-API-DMAC7.html)
EP (1) EP2810657B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013177372A (cg-RX-API-DMAC7.html)
KR (1) KR20150000874A (cg-RX-API-DMAC7.html)
CN (1) CN104080478A (cg-RX-API-DMAC7.html)
CA (1) CA2861261A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491453A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN06911A (cg-RX-API-DMAC7.html)
PH (1) PH12014501689A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201606271RA (cg-RX-API-DMAC7.html)
TW (1) TW201336526A (cg-RX-API-DMAC7.html)
WO (1) WO2013115201A1 (cg-RX-API-DMAC7.html)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
AU6919598A (en) * 1997-04-17 1998-11-13 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4496406B2 (ja) 2003-03-07 2010-07-07 参天製薬株式会社 4−ピリジルアルキルチオ基を置換基として有する新規化合物
CN1897918A (zh) * 2003-11-17 2007-01-17 阿尔萨公司 包含两亲性分子作为混悬载体的组合物和剂型
JP4626353B2 (ja) 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
EP1843746B1 (en) * 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
PL1845942T3 (pl) * 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
AU2005325510B2 (en) * 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
JP4585978B2 (ja) 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP4834441B2 (ja) 2005-03-31 2011-12-14 参天製薬株式会社 ピリミジニルアルキルチオ基を有する新規環式化合物
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
JP4825636B2 (ja) 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2,3,4−テトラヒドロキノキサリン誘導体
KR20090086539A (ko) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
EP2128156A4 (en) 2007-01-29 2011-05-18 Santen Pharmaceutical Co Ltd NEW OXADIAZOL DERIVATIVES AND THIADIAZONE DERIVATIVES WITH THE NEOVASCULARIZATION HEMMENDER EFFECT
EP2151436B1 (en) 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2009035068A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規1,3,3-トリメチル-7-フェニル-3,4-ジヒドロ-1h-キノキサリン-2-オン誘導体
AU2010271746B2 (en) 2009-07-17 2014-07-03 Santen Pharmaceutical Co., Ltd. 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
PH12014501689A1 (en) 2014-10-20
EP2810657A4 (en) 2015-07-29
US20150011518A1 (en) 2015-01-08
EA201491453A1 (ru) 2014-12-30
WO2013115201A1 (ja) 2013-08-08
IN2014DN06911A (cg-RX-API-DMAC7.html) 2015-05-15
EP2810657B1 (en) 2016-09-21
CA2861261A1 (en) 2013-08-08
SG10201606271RA (en) 2016-09-29
SG11201404230QA (en) 2014-10-30
KR20150000874A (ko) 2015-01-05
CN104080478A (zh) 2014-10-01
EP2810657A1 (en) 2014-12-10
JP2013177372A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
EP3843704B1 (en) Emulsion formulations of multikinase inhibitors
Boyd et al. Hexosomes formed from glycerate surfactants—Formulation as a colloidal carrier for irinotecan
CN101959501B (zh) 稳定的含多西紫杉醇的单液药用组合物
Iwanaga et al. Application of organogels as oral controlled release formulations of hydrophilic drugs
RS53329B (sr) Postupak i smeša za lečenje inflamatornih poremećaja
CN102740833A (zh) 吉西他滨衍生物的肠胃外制剂
US11147811B2 (en) Composition comprising fine particle and process thereof
JP2023536102A (ja) Jak阻害剤およびラウレス-4を含有する局所配合物
US20120082627A1 (en) Otic foam formulations
CN114712308A (zh) 药物制剂
JP5574965B2 (ja) 新規タキソイドに基づく組成物
US20140234227A1 (en) Foam formulations
JP2009503097A (ja) 酢酸プレドニゾロンの経口懸濁液
WO2014199455A1 (ja) メマンチン経皮吸収型貼付製剤
JP2016104708A (ja) アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
WO2021124044A1 (en) Pharmaceutical composition of cyclooxygenase – 2 inhibitors
EP2810657B1 (en) Non-aqueous liquid composition
Salimi et al. Ocular delivery of ketorolac tromethamine using microemulsion as a vehicle: Design, evaluation, and transcorneal permeation
CN101912362B (zh) 一种替尼泊苷静脉注射用脂肪乳预乳化浓缩液及其制备方法
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤
JP4686144B2 (ja) 油脂性軟膏剤
WO2023114832A9 (en) Stable formulations of shr0302
CN101106995B (zh) 在非水极性溶剂中增加溶解度的10-羟基喜树碱类化合物的药物制剂
JP2016104709A (ja) シスチン誘導体を含有する非水性注射剤及びデポ形成方法
Harmon Nano-Emulsion Formulations for Injection & Oral Administration